Nadir CA-125 has prognostic value for recurrence, but not for survival in patients with ovarian cancer
Abstract The objective of this study was to evaluate the nadir CA-125 in patients with epithelial ovarian cancer. A total of 168 patients who achieved complete remission (no clinical and radiological signs, CA-125 ≤ 35 U/ml) after first-line treatment were enrolled in the study. The relationship bet...
Guardado en:
Autores principales: | Szymon Piatek, Grzegorz Panek, Zbigniew Lewandowski, Dominika Piatek, Przemyslaw Kosinski, Mariusz Bidzinski |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/268c85ed85a24e249946fd10674d4b6b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lentinan Combined with (125)I Brachytherapy for Recurrent Ovarian Cancer
por: Qin Jiang, et al.
Publicado: (2021) -
RELATION BETWEEN REGULATORY T CELLS, CA-125 LEVEL AND TUMOR MASS IN OVARIAN CANCER PATIENTS
por: E. R. Chernykh, et al.
Publicado: (2014) -
Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
por: Quan Quan, et al.
Publicado: (2021) -
El nadir de un modelo
por: Davide Maffi
Publicado: (2021) -
Therapeutic effects and prognostic factors of 125I brachytherapy for pelvic recurrence after early cervical cancer surgery
por: Rui Wang, et al.
Publicado: (2021)